Prevail Therapeutics
New York · Founded 2017
About Prevail Therapeutics
Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases. Prevail was launched in 2017 by The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, and OrbiMed, and is headquartered in New York, NY.
Company Facts
- Founded: 2017
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $129.0M
- Funding stage: M&A
- Last round: Series B (Mar 2019)
- Ticker: nasdaq:PRVL
- Website: prevailtherapeutics.com
- Phone: 917-336-9310
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/prevail-therapeutics-59483 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.